Courts Consolidate Xarelto Bleeding Lawsuits

Courts Consolidate Xarelto Bleeding Lawsuits

Big Pharma started 2015 with the news that two U.S. courts consolidated groups of Xarelto lawsuits that claim the blood thinner caused severe bleeding, some of which caused drug recipients to die.

An oral blood thinner developed and sold by Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Xarelto (rivaroxaban), hit the U.S. market in July 2011 and quickly grew into a popular alternative to an older medication, warfarin. The drug’s makers marketed the drug as superior to warfarin.

Unlike warfarin, Xarelto has no dietary restrictions or blood tests but causes more gastrointestinal bleeds. This excessive bleeding led to serious complications, and patients and families soon turned to litigation as compensation for damages.

The first consolidation order came in December 2014 when the U.S. Judicial Panel on Multidistrict District Litigation (JPML) transferred about two dozen cases in Louisiana federal court. The defendants, drug giants Bayer and Johnson & Johnson’s Janssen Pharmaceuticals unit, claim there were not enough similarities to go ahead with the order, but the panel disagreed.


About TriMark

TriMark Legal Funding provides non-recourse pre-settlement and post-settlement Xarelto lawsuit loans to injured plaintiffs nationwide.

This post originally appeared here: https://www.drugwatch.com/news/2015/01/28/courts-consolidate-xarelto-janssen-lawsuits/

Click here to see the full original article.

Still have questions?

Call (877) 932-2628 and speak with one of our legal funding experts.

* Word-Use Disclaimer

Legal funding is not a loan. It is the non-recourse purchase of an equitable lien in plaintiffs’ legal claims. Words such as ‘loans,’ ‘lending,’ ‘borrow,’ etc., are used for marketing purposes only.
More info

TriMark Legal Funding LLC
1056 Green Acres Rd #102
Eugene, OR 97408